Cargando…

Metastatic renal cell carcinoma: the first report of unilateral fundus hemorrhage induced by sorafenib

BACKGROUND: Renal cell carcinoma (RCC) is the most common type of kidney tumor with increasing incidence. Tyrosine Kinase Inhibitors (TKIs) are considered important treatment in the management of metastatic RCC. Some previous studies demonstrated that sorafenib treatment is associated with a signifi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Zhi Yong, Fan, Xin Xiang, Wang, Yan Jun, Yao, Kai, Liu, Zhuo Wei, Pan, Wen Tao, Ye, Yun Lin, Yang, Ping, Huang, Yi Chuan, Wu, Zhi Ming, Zhou, Fang Jian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5085219/ https://www.ncbi.nlm.nih.gov/pubmed/27174916 http://dx.doi.org/10.18632/oncotarget.9285

Ejemplares similares

Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors
por: Zhang, Hai-Liang, et al.
Publicado: (2017)

Sorafenib in the management of metastatic renal cell carcinoma
por: Guevremont, C., et al.
Publicado: (2009)

Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial
por: Procopio, G, et al.
Publicado: (2011)

Development and Evaluation of a Deep Learning System for Screening Retinal Hemorrhage Based on Ultra-Widefield Fundus Images
por: Li, Zhongwen, et al.
Publicado: (2020)

Experience of Sorafenib as First-Line Treatment in Metastatic Renal Cell Carcinoma in a Tertiary Care Centre
por: Saxena, Mohith, et al.
Publicado: (2018)

Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: Results from a multicenter study
por: Zhang, Hailiang, et al.
Publicado: (2009)

Successful treatment with sorafenib for sunitinib‐refractory metastatic papillary renal cell carcinoma: Potential impact of Raf overexpression on predicting the efficacy of sorafenib
por: Morinaga, Ryota, et al.
Publicado: (2018)

Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinoma
por: Aziz, Saadia A, et al.
Publicado: (2014)

Complete Response to Sorafenib Rechallenge in a Patient with Metastatic Renal Cell Carcinoma
por: Kasahara, Ryo, et al.
Publicado: (2017)

Sequential Treatment Based on Sunitinib and Sorafenib in Patients with Metastatic Renal Cell Carcinoma
por: Schlemmer, Marcus, et al.
Publicado: (2019)

Bilateral Fundus Excyclotorsion in Unilateral Superior Oblique Palsy Confirmed by MR Imaging
por: Hong, Eun Hee, et al.
Publicado: (2020)

Evaluation of Fundus-First Laparoscopic Cholecystectomy
por: Gupta, Amit, et al.
Publicado: (2004)

Laparoscopic retrograde (fundus first) cholecystectomy
por: Kelly, Michael D
Publicado: (2009)

Efficacy of sequential therapies with sorafenib-sunitinib versus sunitinib-sorafenib in metastatic renal cell carcinoma: A systematic review and meta-analysis
por: Wen, Tingyu, et al.
Publicado: (2017)

A meta-analysis of efficacy and safety of sorafenib versus other targeted agents for metastatic renal cell carcinoma
por: Wang, Hai-Tao, et al.
Publicado: (2019)

Stabilization of metastatic myxopapillary ependymoma with sorafenib
por: Fegerl, Gundula, et al.
Publicado: (2012)

Effects and Side Effects of Using Sorafenib and Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma
por: Randrup Hansen, Caroline, et al.
Publicado: (2017)

Clinicopathological and prognostic factors for long-term survival in Chinese patients with metastatic renal cell carcinoma treated with sorafenib: a single-center retrospective study
por: Zhang, Hai-Liang, et al.
Publicado: (2015)

Fluorescein Angiographic Abnormalities in the Contralateral Eye with Normal Fundus in Children with Unilateral Coats' Disease
por: Jung, Eun Hye, et al.
Publicado: (2018)

Comparison of efficacy, safety, and quality of life between sorafenib and sunitinib as first-line therapy for Chinese patients with metastatic renal cell carcinoma
por: Cai, Wen, et al.
Publicado: (2017)

Fundus autofluorescence imaging of subinternal limiting membrane hemorrhage in anemic retinopathy
por: Lekha, T, et al.
Publicado: (2017)

Comparing Conventional and Deep Feature Models for Classifying Fundus Photography of Hemorrhages
por: Aziz, Tamoor, et al.
Publicado: (2022)

Fundus first as the standard technique for laparoscopic cholecystectomy
por: Cengiz, Yucel, et al.
Publicado: (2019)

Fundus imaging: Conventional fundus drawings versus ultrawidefield fundus photography
por: Shah, Rakesh D, et al.
Publicado: (2023)

Novel Microcrystal Formulations of Sorafenib Facilitate a Long-Acting Antitumor Effect and Relieve Treatment Side Effects as Observed With Fundus Microcirculation Imaging
por: Wang, Junxiao, et al.
Publicado: (2021)

Development of Nephrotic Syndrome after Administration of Sorafenib in a Case of Metastatic Renal Cell Carcinoma
por: Okuno, Yumiko, et al.
Publicado: (2011)

Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib
por: Pantaleo, Maria Abbondanza, et al.
Publicado: (2012)

Liproxstatin-1 attenuates unilateral ureteral obstruction-induced renal fibrosis by inhibiting renal tubular epithelial cells ferroptosis
por: Zhang, Bo, et al.
Publicado: (2021)

Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis
por: Sheng, Xinan, et al.
Publicado: (2016)

Renal cell carcinoma and the use of sorafenib
por: Larkin, James MG, et al.
Publicado: (2006)

Quantification of Plasma Cell-Free DNA(1) in Predicting Therapeutic Efficacy of Sorafenib on Metastatic Clear Cell Renal Cell Carcinoma
por: Feng, Gang, et al.
Publicado: (2013)

Fundus images analysis using deep features for detection of exudates, hemorrhages and microaneurysms
por: Khojasteh, Parham, et al.
Publicado: (2018)

The impact of FGFR1 and FRS2α expression on sorafenib treatment in metastatic renal cell carcinoma
por: Ho, Thai H, et al.
Publicado: (2015)

Comparative Efficacy, Safety, and Costs of Sorafenib vs. Sunitinib as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis
por: Deng, Huan, et al.
Publicado: (2019)

A New Approach to the Treatment of Metastatic Paraganglioma: Sorafenib
por: Gunaldi, Meral, et al.
Publicado: (2014)

Phase I/II Trial of Sorafenib in Combination with Vinorelbine as First-Line Chemotherapy for Metastatic Breast Cancer
por: Ferrario, Cristiano, et al.
Publicado: (2016)

The Cost Effectiveness of Donafenib Compared With Sorafenib for the First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma in China
por: Meng, Rui, et al.
Publicado: (2022)

Prognostic Impact of Metastatic Site in Patients Receiving First-Line Sorafenib Therapy for Advanced Hepatocellular Carcinoma
por: Ielasi, Luca, et al.
Publicado: (2023)

Development of a nomogram using fundus photography to predict glaucoma progression in patients showing disc hemorrhage
por: Kim, Sangah, et al.
Publicado: (2020)

Cost‐effectiveness analysis of sintilimab plus IBI305 versus sorafenib for unresectable hepatic cell carcinoma in China
por: Xu, Zhe, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1pugj49p58k9f6nboh6bjtsr7m